T1	Participants 52 79	superficial bladder cancer.
T2	Participants 321 420	in patients with primary or recurrent superficial bladder tumors, including carcinoma in situ (CIS)
T3	Participants 771 772	.
T4	Participants 773 923	Reported are the incidence of side effects in 165 patients and the recurrence rate of tumors in 308 patients after a follow-up period of twelve months
